APVO:NSD-Aptevo Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.51

Change

-0.10 (-1.51)%

Market Cap

USD 0.04B

Volume

0.07M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aptevo Therapeutics Inc (APVO) Stock Analysis:
Based on the Aptevo Therapeutics Inc stock forecasts from 2 analysts, the average analyst target price for Aptevo Therapeutics Inc is USD 0.00 over the next 12 months. Aptevo Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Aptevo Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Aptevo Therapeutics Inc’s stock price was USD 6.51. Aptevo Therapeutics Inc’s stock price has changed by -0.74% over the past week, -1.61% over the past month and -79.38% over the last year.

About

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing APVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.28% 42% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.28% 42% F 20% F
Trailing 12 Months  
Capital Gain -79.38% 13% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.38% 13% F 6% F
Trailing 5 Years  
Capital Gain 177.02% 81% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 177.02% 81% B- 84% B
Average Annual (5 Year Horizon)  
Capital Gain 853.33% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 853.33% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 2,207.67% 2% F 1% F
Risk Adjusted Return 38.65% 68% D+ 56% F
Market Capitalization 0.04B 11% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.80 20% F 23% F
Price/Book Ratio 5.22 26% F 24% F
Price / Cash Flow Ratio -1.21 16% F 57% F
EV/EBITDA 0.04 93% A 98% A+
Management Effectiveness  
Return on Equity -631.60% 4% F 10% F
Return on Invested Capital -74.96% 28% F 11% F
Return on Assets -29.80% 40% F 12% F
Debt to Equity Ratio 120.85% 11% F 17% F
Technical Ratios  
Short Ratio 0.36 91% A- 87% B+
Short Percent 7.97% 26% F 21% F
Beta 6.70 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector